| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $63.5M | +53.5% |
| SG&A Expense | $20.5M | +23.4% |
| Operating Income | -$84.0M | -44.9% |
| Pre-tax Income | -$72.9M | -25.8% |
| Income Tax | $1.2M | — |
| Net Income | -$74.2M | -27.9% |
| EPS (Basic) | -$4.05 | +40.7% |
| EPS (Diluted) | -$4.05 | +40.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $253.8M | +79.7% |
| Current Assets | $257.4M | +75.2% |
| Total Assets | $261.0M | +70.7% |
| Current Liabilities | $9.7M | -16.7% |
| Total Liabilities | $9.7M | -20.0% |
| Stockholders' Equity | $251.3M | +78.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$60.1M | -1.7% |
| Capital Expenditures | $208K | +33.3% |
| Investing Cash Flow | -$138K | +11.5% |
| Financing Cash Flow | $173.4M | +1.0% |
| Free Cash Flow | -$60.3M | -1.8% |